CAPTURE -Contemporary Prospective understanding of Migraine RWE

  • Research type

    Research Study

  • Full title

    Multi-country, observational, prospective, longitudinal study to describe the burden of illness and treatment patterns in patients with migraine (CAPTURE- ContemporAry ProspecTive Understanding of Migraine Real World Evidence Study)

  • IRAS ID

    324523

  • Contact name

    Francisco Javier Carod Artal

  • Contact email

    Javier.CarodArtal@nhs.scot

  • Sponsor organisation

    Abbvie UK

  • Clinicaltrials.gov Identifier

    NA, NA

  • Duration of Study in the UK

    2 years, 8 months, 4 days

  • Research summary

    This is a multi-country, observational, prospective, longitudinal study. This study will be conducted in Greece, Ireland, Turkey, Switzerland, Spain, Portugal, Italy, Germany, Netherlands, United Kingdom, France, Brazil, Colombia, United Arab Emirates and Kuwait, Canada.
    The study is based on prospective collection of data from patient-reported outcomes (PROs) completed via a mobile application, as well as data documented in the electronic case report form (eCRF) via physicians. Retrospective data from patients' medical records will also be collected, for example information on demographics and disease characteristics. There will be no changes to patient management for the purposes of any part of the study and no additional tests, investigations or visits will be required. All study visits will align with standard practice visits.

    The population for this study is adult patients who have been diagnosed with migraines and are on migraine treatment(s) at study start. It is expected to recruit about 2000 patients in total across 15 different countries in this 24-month study. There will be 7 health centres in the UK.
    The main purpose of the study is to describe the burden of illness and treatment patterns in patients with migraine.

  • REC name

    London - Surrey Borders Research Ethics Committee

  • REC reference

    23/PR/0494

  • Date of REC Opinion

    23 May 2023

  • REC opinion

    Further Information Favourable Opinion